CCTC EXAM 2 FINAL PAPER 2026
VERIFIED SOLUTIONS AND ANSWERS
GRADED A+
⩥ S&S of acute rejection s/p lung tx.
Answer: Low grade temp, non-specific respiratory sx, dyspnea,
tachypnea, fatigue, plural effusions, chest pressure
⩥ Bronchiolitis obliterans (with or without BOS).
Answer: chronic allograft rejection-seen pathologically as dense fibrous
scar tissue affecting small airways
⩥ COPD: Emphysema.
Answer: most common indication for lung tx
⩥ Cardiac dysrhythmias.
Answer: most common s/p lung tx due to irritation of pericardium
subsequent to intrusion into pericardial spacer or electrolyte imbalances
r/t CPB (cardiopulmonary bypass & diuretic r/t fluid shifts)
⩥ lung biopsy.
Answer: only true confirmation of rejection s/p lung tx
,⩥ PFT (pulmonary function test).
Answer: first line to r/o rejection s/p lung tx
⩥ AMR treatment s/p lung tx.
Answer: Rituximab, Plasmapheresis, immunoglobin
⩥ CLAD (chronic lung allograft dysfunction).
Answer: Progressive form of chronic rejection, irreversible, restrictive
functional changes with fibrotic processes
⩥ Most common indications for pediatric lung tx.
Answer: CF, Primary Pulm Htn, Congential Heart disease, Pulm Htn
⩥ Evaluate in Pediatric Lung Tx recipient with CF.
Answer: Sinuses
⩥ Pediatric Lung Tx recipient use LAS score.
Answer: greater than 12 y.o.
⩥ Pediatric Lung recipient priority 1 & 2.
Answer: <12 years old, clinical data updated every 6 months(except
heart Cath), Priority 1 more urgent status,
, ⩥ pediatric lung tx R/D CMV+ treatment.
Answer: Iv Ganciclovir x1 week, then oral valganiclovir x6 mos
⩥ treatment of AMR s/p lung tx.
Answer: rituximab
⩥ CF pediatric lung tx recipient.
Answer: dual lung tx performed
⩥ LAS score follow up frequency.
Answer: stable-follow every 8-12 wks, LAS > 50 functional status every
2 wks, < 50 every 6 months
⩥ LAS (Lung Allocation Score).
Answer: Tool used to estimate medical urgency, DOES NOT predict
how long a patient will survive without a transplant
⩥ Procalcitonin (PCT).
Answer: Biomarker for assessment of early bacterial infections, Do not
elevate during virus or rejection
⩥ UNOS policy 6.5.E(allocation of heart-lungs).
VERIFIED SOLUTIONS AND ANSWERS
GRADED A+
⩥ S&S of acute rejection s/p lung tx.
Answer: Low grade temp, non-specific respiratory sx, dyspnea,
tachypnea, fatigue, plural effusions, chest pressure
⩥ Bronchiolitis obliterans (with or without BOS).
Answer: chronic allograft rejection-seen pathologically as dense fibrous
scar tissue affecting small airways
⩥ COPD: Emphysema.
Answer: most common indication for lung tx
⩥ Cardiac dysrhythmias.
Answer: most common s/p lung tx due to irritation of pericardium
subsequent to intrusion into pericardial spacer or electrolyte imbalances
r/t CPB (cardiopulmonary bypass & diuretic r/t fluid shifts)
⩥ lung biopsy.
Answer: only true confirmation of rejection s/p lung tx
,⩥ PFT (pulmonary function test).
Answer: first line to r/o rejection s/p lung tx
⩥ AMR treatment s/p lung tx.
Answer: Rituximab, Plasmapheresis, immunoglobin
⩥ CLAD (chronic lung allograft dysfunction).
Answer: Progressive form of chronic rejection, irreversible, restrictive
functional changes with fibrotic processes
⩥ Most common indications for pediatric lung tx.
Answer: CF, Primary Pulm Htn, Congential Heart disease, Pulm Htn
⩥ Evaluate in Pediatric Lung Tx recipient with CF.
Answer: Sinuses
⩥ Pediatric Lung Tx recipient use LAS score.
Answer: greater than 12 y.o.
⩥ Pediatric Lung recipient priority 1 & 2.
Answer: <12 years old, clinical data updated every 6 months(except
heart Cath), Priority 1 more urgent status,
, ⩥ pediatric lung tx R/D CMV+ treatment.
Answer: Iv Ganciclovir x1 week, then oral valganiclovir x6 mos
⩥ treatment of AMR s/p lung tx.
Answer: rituximab
⩥ CF pediatric lung tx recipient.
Answer: dual lung tx performed
⩥ LAS score follow up frequency.
Answer: stable-follow every 8-12 wks, LAS > 50 functional status every
2 wks, < 50 every 6 months
⩥ LAS (Lung Allocation Score).
Answer: Tool used to estimate medical urgency, DOES NOT predict
how long a patient will survive without a transplant
⩥ Procalcitonin (PCT).
Answer: Biomarker for assessment of early bacterial infections, Do not
elevate during virus or rejection
⩥ UNOS policy 6.5.E(allocation of heart-lungs).
